| |
PFS
|
|---|
|
HR
|
95% CI
|
p-value
|
|---|
|
Univariate
|
|
Age
|
1.13
|
0.59–2.18
|
0.71
|
|
Gender
|
0.84
|
0.40–1.73
|
0.63
|
|
Smoking
|
0.73
|
0.38–1.40
|
0.35
|
|
Grade
|
1.04
|
0.51–2.10
|
0.92
|
|
T.size
|
1.62
|
0.78–3.35
|
0.19
|
|
Laterality
|
1.29
|
0.93–1.79
|
0.13
|
|
LN metastasis
|
1.65
|
1.17–2.34
|
0.005**
|
|
EGFR mutation
|
1.99
|
1.37–2.93
|
< 0.001***
|
|
ROS1
|
0.95
|
0.61–1.47
|
0.81
|
|
ALK
|
1.46
|
1.03–2.07
|
0.03*
|
|
PD-1
|
1.36
|
0.81–2.29
|
0.24
|
|
PD-L1
|
1.20
|
0.84–1.73
|
0.31
|
|
ROS1 rearrangement
|
1.09
|
0.70–1.69
|
0.70
|
|
Multivariate
|
|
Laterality
| | | |
|
LN metastasis
|
1.59
|
1.11–2.25
|
0.010*
|
|
ALK
|
1.46
|
1.03–2.08
|
0.04*
|
|
EGFR
|
2.08
|
1.37–3.15
|
< 0.001***
|
- HR hazard ratio, PFS progression-free survival, LN lymph node, EGFR epidermal growth factor receptor, ROS1 c-ros oncogene1, ALK anaplastic lymphoma kinase, PD-1 programmed cell death-1, PD-L1 programmed cell death ligand-1
- Cox regression analysis was used
- ***Significant at p < 0.001. **Significant at p < 0.01. *Significant at p < 0.05
